Astrazeneca (AZN) Net Margin (2009 - 2026)

Astrazeneca has reported Net Margin for 18 years, with the latest figure at 16.3% in Q2 2026.

• On a quarterly basis, Net Margin fell 66.0% year-over-year to 16.3% in Q2 2026; TTM through Jun 2026 was 17.05%, a 211.0% increase from a year earlier, with the FY2025 full-year figure at 9.17%, up 460.0% from the prior year.
• Net Margin was 16.3% for Q2 2026 at Astrazeneca, down from 20.25% in the prior quarter.
• The five-year high for Net Margin was 21.58% in Q1 2025, with the low at 2.96% in Q4 2023.
• Average Net Margin over 5 years is 13.28%, with a median of 14.97% recorded in 2022.
• The largest YoY upside for Net Margin was 1832 bps in 2022 against a maximum downside of 1812 bps in 2022.
• Over 5 years, Net Margin stood at 8.04% in 2022, then tumbled by 63 bps to 2.96% in 2023, then soared by 260 bps to 10.66% in 2024, then jumped by 41 bps to 15.01% in 2025, then gained by 9 bps to 16.3% in 2026.
• The last three Net Margin figures came in at 16.3% (Q2 2026), 20.25% (Q1 2026), and 15.01% (Q4 2025), per Business Quant data.